Sebia opens its new affiliate in Montréal

After a long-term distribution partnership with Somagen Diagnostics, which represented Sebia in the Canadian market for many years, the new Canadian Sebia team is excited to engage with customers directly to provide a world-class service and clinically differentiated innovations. The Sebia Canada team will be dedicated and ready to support laboratories across the country with sales, application specialists and after sales engineers. Sebia Canada will also provide scientific services, technical and clinical education, and a “Knowledge Center” service to daily support and assist laboratories in interpreting Sebia laboratory tests.

Sebia Canada is an important step forward in the development of the global company and is fully supported by its shareholders Caisse de dépôt et placement du Québec, CVC Capital Partners and Téthys Invest.

“Starting our direct operations in Canada will enable Sebia to successfully strengthen  its undisputed leadership in multiple myeloma management, to continue its development in the diagnostic and monitoring of diabetes and propose other innovative biomarkers using our core technology.” says Jean-Marc Chermette, CEO at Sebia.

About Sebia

Sebia a global specialty diagnostic company that develops, manufactures, and commercializes IVD tests and analyzers dedicated to the in vitro diagnosis of cancer, inflammatory diseases, diabetes, and hemoglobin disorders. Sebia’s focus on electrophoresis techniques enables it to maintain a sustained R&D program, providing access to genuine innovations in any lab. Both agarose gel and capillary assays, and their dedicated automation, are designed to be integrated into the same routine workflow; for gel (Assist, Hydrasys 2 Scan) and for capillary electrophoresis (Capillarys 3 family instruments , stand alone or in work cell configuration up to three instruments with tube loader, Minicap Flex Piercing).